Craig S. Gibbs
Director Ejecutivo en Asher Biotherapeutics, Inc. .
Fortuna: - $ al 31/05/2024
Cargos activos de Craig S. Gibbs
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Asher Biotherapeutics, Inc.
 Asher Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Asher Biotherapeutics, Inc. engages in the research and development of immunotherapy for cancer. The company was founded by Ivana Djuretic and Andy Yeung in 2019 and is headquartered in South San Francisco, CA. | Director Ejecutivo | 01/09/2020 | - |
Historial de carrera de Craig S. Gibbs
Antiguos cargos conocidos de Craig S. Gibbs.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ARIDIS PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 09/04/2015 | 27/03/2023 |
| Independent Dir/Board Member | 09/04/2015 | 27/03/2023 | |
| FORTY SEVEN, INC. | Corporate Officer/Principal | 01/09/2015 | 01/07/2020 |
Tobira Therapeutics, Inc. /Old/
 Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Director/Miembro de la Junta | 23/06/2014 | 01/09/2016 |
| Independent Dir/Board Member | 23/06/2014 | 01/09/2016 | |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/1992 | 01/01/2013 |
Formación de Craig S. Gibbs.
| Massey University | Undergraduate Degree |
| University of Glasgow | Doctorate Degree |
| Golden Gate University | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 7 |
| Nueva Zelanda | 2 |
| Reino Unido | 2 |
Operativa
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
| Corporate Officer/Principal | 2 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 4 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ARIDIS PHARMACEUTICALS, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Asher Biotherapeutics, Inc.
Asher Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Asher Biotherapeutics, Inc. engages in the research and development of immunotherapy for cancer. The company was founded by Ivana Djuretic and Andy Yeung in 2019 and is headquartered in South San Francisco, CA. | Commercial Services |
- Bolsa de valores
- Insiders
- Craig S. Gibbs
- Experiencia
